fda tirzepatide update says the weight-loss drug shortage is over F.D.A. Approves New Obesity Drug

Dr Malige said, Mounjaro (tirzepatide) is a dual agonist, which means it mimics another hormone that is GIP (glucose-dependent insulinotropic polypeptideas) as well as GLP-1 (Glucagon-Like Peptide-1 receptor agonist)

Improved Heart Health GLP-1 medications have been shown to reduce the risk of major cardiovascular events in people with diabetes and obesity

Unlike acetaminophen or ibuprofen, which you can take when you need them and stop when you dont, after halting Ozempic and other semaglutide medications, a users appetite will come back stronger than before

New clinical data suggests body composition may become a major focus of next-generation obesity care

7 , e2237 (2016)